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This study was designed to evaluate coagulation and fibrinolysis activity and their relationship with left ventricular function in 
young obese subjects with central fat distribution. We assessed coagulation and fibrinolysis activity by evaluation of factor VII 
activity, fibrinogen and plasminogen, plasminogen activator inhibitor (PAl), and tissue plasminogen activator antigen basally 
(tPA1) and after venous occlusion (tPA2). These measures were evaluated in young (<40 years) obese subjects with central fat 
distribution (n = 19) and in comparable lean subjects (n = 20). Blood glucose, triglycerides, total and high-density lipoprotein 
(HDL) cholesterol, apolipoprotein (apo) A1 and apo B, fasting immunoreactive insulin, and lipoprotein(a) levels were also 
measured by current methods. Left ventricular ejection fraction (LVEF) and peak filling rate (PFR) determined by radionuclide 
angiocardiography and left ventricular mass (LVM) and LVM indexed for body height (LVM/H) determined by echocardio- 
graphic study were calculated. Central obesity was evaluated by the waist to hip ratio (WHR) according to the criteria of the 
Italian Consensus Conference of Obesity. Factor VII (P < .001), fibrinogen (P < .001), plasminogen (P < .001), PAl activity 
(P < .001), tPA1 (P < .02), fasting blood glucose (P < .01), apo B (P < .02), and immunoreactive insulin (P < .01) were 
significantly higher in obese than in lean subjects. In contrast, HDL cholesterol (P < .01), tPA2 (P < .01), LVEF (P < .001), and 
PFR (P < .02) were significantly lower in obese than in lean subjects. In all subjects, WHR correlated directly with fibrinogen and 
inversely with tPA2; LVEF correlated inversely with tPA1, PAl, and fibrinogen; and PFR correlated inversely with factor VII 
activity. Multiple regression analysis indicated that WHR and PAl were independent predictors of LVEF. These results indicate 
that obese subjects with central fat distribution are characterized by a hypercoagulable state associated with a silent left 
ventricular dysfunction. Such alterations might be responsible for the higher cardiovascular risk in subjects with central 
obesity. 
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O BESITY is an important risk factor for cardiovascular disease, especially when there is a central fat distribu- 
tion. Several indications suggest an independent role of 
obesity in promoting cardiovascular disease; however, this 
has not been universally accepted. 1 In addition, recent 
follow-up results of the Harvard Growth Study indicate that 
the risk of morbidity from coronary heart disease and 
atherosclerosis increased among men and women who had 
been overweight in adolescence. 2 The effects of obesity in 
adolescence on adult mortality have been demonstrated to
reflect the central deposition of fat that occurs in adoles- 
cence.3, 4 
On the other hand, alterations in hemostatic function are 
emerging predictors of coronary heart disease or cardiac 
events. In fact, some epidemiological data indicate that 
activated coagulation and impaired fibrinolytic function 
might be associated with an increased risk of dying of 
cardiovascular disease. 5-s In some of these studies, coagula- 
tion or fibrinolysis activity was also related to body mass 
index (BMI) or waist to hip ratio (WHR). 6,8 
These data might suggest an early connection between 
obesity and atherosclerosis and its clinical manifestations. 
Our previous data indicated a depressed ejection fraction at 
rest and after exercise in young normotensive obese sub- 
jects without major risk factors for cardiovascular dis- 
ease. 9,1° In the same subjects, a decrease in [3-adrenergic 
receptor density and an impaired diastolic function were 
found.11,i2 
Nevertheless, few data are available on the relationship 
between obesity, hemostatic activity, and left ventricular 
function.8,13-~5 
In the present study, coagulation and fibrinolysis function 
have been evaluated in young normotensive obese subjects 
with central fat distribution and without major risk factors 
for cardiovascular disease or events, ie, smoking, hyperten- 
sion, diabetes, and lipid abnormalities. Our final goal was to 
recognize relationships among body fat distribution, hemo- 
static measurements, and left ventricular function in obese 
subjects with central fat distribution. 
SUBJECTS AND METHODS 
Subjects 
A total of 39 subjects, 19 obese and 20 lean healthy controls, 
younger than 40 years were included in this study. Obese subjects 
were recruited from individuals attending the obesity center of the 
Internal Medicine Department at the University of Palermo. Lean 
controls were chosen from a group of subjects undergoing a clinical 
evaluation and found to be healthy. Subjects were considered 
obese according to BMI values proposed by the Italian Consensus 
Conference on Obesity. ~6 Cutoff values for obesity were a BMI of 
at least 30.5 kg/m 2 for men and 27.3 kg/m 2 for women. Lean 
subjects were selected on the basis of BMI values of less than 24.7 
kg/m 2 for women and 25 kg/m z for men. Each subject's fat 
distribution was assessed by measuring WHR in the standing 
position as previously reported. 9,1°,12 Central fat distribution was 
defined on the basis of the sex-specific 85th percentile of WHR 
values. 16 In view of this, the cutoff value for central obesity was 
considered at least 0.81 for women and 0.92 for men. According to 
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these criteria, obese subjects with peripheral fat distribution 
(WHR < 0.81 for women and < 0.92 for men) were excluded. 
Following this procedure, subjects were subdivided into two 
groups: group 1 (lean subjects), 10 men and 10 women aged 24 to 
39 years (mean, 34 _+ 5) with a BM1 mean value of 23.3 _+ 0.8 and a 
WHR mean value of 0.75 --- 0.04; and group 2 (obese subjects with 
central fat distribution), nine men and 10 women aged 28 to 38 
years (mean, 33 _+ 4) with a BMI mean value of 36.3 -+ 4.7 and a 
WHR mean value of 0.93 _+ 0.06. 
All subjects were normotensive (systolic blood pressure consis- 
tently < 140 mm Hg and diastolic blood pressure < 90 mm Hg) and 
matched as closely as possible with regard to age, gender, and 
height (Table 1). Arterial blood pressure was measured with an 
appropriately large cuff in obese subjects. 1,9,1°,12 
Exclusion criteria included smoking habits, insulin-dependent or 
-independent diabetes mellitus, hyperlipoproteinemia (total choles- 
terol > 220 mg/dL), endocrine and cardiovascular disease, hyper- 
tension, electrolyte imbalance, alcoholism, drug addiction, and 
psychiatric problems. 
All obese subjects had been left untreated for at least 2 weeks 
before the study. During this withdrawal period, no significant 
changes in body weight were observed. This study was approved by 
the Ethics Committee of our Institute, and each patient gave 
informed consent after a detailed escription of the study proce- 
dure. 
Preliminary investigations included determination f blood and 
urinary electrolytes, creatinine clearance, blood glucose, oral 
glucose tolerance, total serum cholesterol, high-density lipoprotein 
(HDL) cholesterol, and triglycerides. Creatinine clearance, serum 
and urinary electrolytes, and the oral glucose tolerance test were 
used to exclude subjects with renal impairment, electrolyte imbal- 
ance, and diabetes mellitus, respectively. These measurements did 
not differ significantly between lean and obese subjects. 
Laboratory Methods 
Venous blood samples were drawn after an overnight fast using a 
1.2-mm siliconized needle without or with minimal stasis. We 
determined the following in serum using conventional enzymatic 
methods (Boehringer Mannheim, Milano, Italy): blood glucose 
(Glucose Oxidase), triglycerides (Glycerol Phosphate Oxidase), 
Table 1. Characteristics of Lean and Obese Subjects 
Characteristic Lean (n = 20) Obese (n = 19) 
Gender (M/F) 10/10 9/10 
Age (yr) 34 -+ 5 33 -4- 4 
Height (cm) 165 -+ 8.3 163 -+ 8.5 
BMI (kg/m 2) 23.3 -+ 0.8 36.3 -4- 4.7* 
WHR 0.75 -+ 0.04 0.93 + 0.06* 
FBG (mg/dL) 89 +- 4 93 -+ 4.5t 
Cholesterol (mg/dL) 176 _+ 18 193 -+ 24 
HDL cholesterol 47.3 _+ 3 41 + 6t  
TG (mg/dL) 120 _+ 21 133 _+ 42 
Lp(a) (mg/dL) 10.3 _+ 5.4 18 + 7t  
ApoA1 (mg/dL) 150 +- 12 153 -+ 24 
Apo B (mg/dL) 105 -+ 15 146 -+ 68:1: 
IRI (ixU/mL) 9.8 +- 3 21.2 -+ 8.31" 
Abbreviations: M, males; F, females; FBG, fasting blood glucose, TG, 
serum triglycerides; Lp (a), lipoprotein (a); IRI, fasting immunoreactive 
insulin. 
*P < .001 vlean. 
tP  < .01 v lean. 
CP < .02 v lean. 
total cholesterol (Cholesterol Oxidase), and HDL cholesterol 
(after precipitation by dextran-magnesium chloride). Apolipopro- 
tein (apo) A1 and B levels were measured by radioimmunodiffu- 
sion (Behring, Scoppito, Italy). 
Immunoreactive insulin levels were measured by the radioimmu- 
noassay double-antibody method using a commercial kit (Sorin, 
Saluggia, Italy). lntrassay variation was 7.5%, and interassay 
variation was 8%; sensitivity for detection of insulin was 2.5 
p,U/mL. 
Lipoprotein(a) levels were assayed by two-site anti-apo(a) immu- 
noradiometric assay with antisera standards and control materials 
supplied by Pharmacia Diagnostic (Uppsala, Sweden). Cross- 
reactivity with plasminogen and apo B is absent up to a concentra- 
tion of 8.5 g/L for plasminogen and 7 g/L for apo B in this assay. 
lnterassay and intrassay variations were les s than 9% and less than 
5%, respectively. 17 
Hemostatic Measurements 
Blood samples for coagulation and fibrinolysis tests were drawn 
in polypropylene tubes containing one tenth final volume of 3.8% 
sodium citrate and kept on crushed ice until centrifugation (4°C at 
2,500 × g for 15 minutes), and plasma was stored in small aliquots 
at -70°C until use. A venous occlusion test was also performed in 
all subjects. A sphygmomanometer cuffwas applied to the contra- 
lateral arm and inflated midway between systolic and diastolic 
pressure for 10 minutes. A further blood sample was obtained 
before deflating the cuff from the occluded arm and separated as 
previously described. 18
Tissue plasminogen activator antigen before (tPA1) and after 
(tPA2) venous occlusion by enzyme-linked immunosorbent assay 
with a commercially available kit (Innogenetics NY, Antwerp, 
Belgium), plasminogen activator inhibitor (PAl) activity by chromo- 
genic substrate assay with reagents obtained from Behring (using 
an automated evice, Behring Chromo Time System; Scoppito, 
Italy), factor VII by a chromogenic substrate assay (Behring 
Chromo Time System), and fibrinogen and plasminogen by radio- 
immunodiffusion (Behring) were determined. 
Analyses were performed in duplicate following the manufactur- 
er's instructions and, in one series for each participant, within 6 
months of sampling. 
Assay of all parameters has been well validated in our labora- 
tory. is Normal values were as follows: tPA antigen, 5 _+ 0.5 ng/mL; 
PAl activity, 3.7 -+ 0.3 U/mL; factor VII activity, 88% -+ 5.2%; 
plasminogen, 10 _+ 1.2 mg/dL; and fibrinogen, 3.4 --- 0.4 g/L. 
Radionuclide Study 
Systolic and diastolic functions were evaluated by radionuclide 
angiocardiography using the blood-gated method reported by 
Bonow et al. 19 A computerized, large-field scintillation camera 
(Starcam 400; General Electric, Horsholm, Denmark) with a 
high-resolution, 1.5-in parallel-hole collimator was used. This 
method has been validated in our laboratory, in particular in obese 
subjects. 9A°,12,2° Left ventricular ejection fraction (LVEF) and peak 
filling rate ([PFR] = end diastolic volume per second) were mea- 
sured. 
Echocardiographic Study 
Two-dimensional nd M-mode echocardiography examination 
was performed using an ESAOTE Biomedica (Ansaldo, Florence, 
Italy) computer-aided ultrasound system equipped with 2.5- and 
3.5-MHz phased-array transducers and a standard video high 
system (VHS). 
Left ventricular mass (LVM) was calculated according to the 
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Devereux method from necropsy-validated studies. 21LVM was 
also related to body height (LVM/H) using the recommendation 
that LVM should be indexed to height instead of body surface area 
for a more accurate valuation of left ventricular hypertrophy 
(LVH). 22 
LVH was assumed in the presence of a LVM/H greater than 2 
standard eviations from the sex-specific mean of a group of 110 
normotensive subjects without a family history of hypertension, 
who provided the normal values for our laboratory. LVH was 
considered present if LVM/H was greater than 120 g in men and 
103 g in women. 
According to these values, none of the obese and lean subjects 
had LVH. 
Statistical Analysis 
Comparisons between lean and obese subjects were performed 
using an unpaired t test. Linear and multiple regression analyses 
were used to calculate correlation coefficients between measure- 
ments of left ventricular function and tests of coagulation or 
fibrinolysis. Independent variables in multiple regression analysis 
were WHR, immunoreactive nsulin, factor VII, and PAI, whereas 
dependent variables were LVEF and PFR. P less than .05 was 
considered statistically significant. All results are expressed as the 
mean - SD. 
RESULTS 
Lean and obese subjects were comparable with regard to 
gender, age, and height. BMI and WHR were obviously 
signifcantly (P < .001) higher in obese than in lean sub- 
jects. In addition, fasting blood glucose (P < .01), lipopro- 
rein(a) (P < .01), apo B (P < .02), and serum insulin 
(P < .01) levels were significantly higher and HDL choles- 
terol values (P < .01) were significantly lower in young 
subjects with central obesity than in lean controls. Total 
cholesterol, serum triglycerides, and apo A1 did not differ 
significantly between obese and lean groups (Table 1). 
Hemostatic Activity and Left Ventffcular Function and 
Structure 
Coagulation and fibrinolytic tests were significantly differ- 
ent between obese and lean subjects. In particular, factor 
VII, fibrinogen, plasminogen, and PAI activity were signifi- 
cantly (P < .001) higher in obese than in lean subjects. In 
addition, tPA1 was significantly higher (P < .02) and tPA2 
significantly ower (P < .05) in obese than in lean subjects. 
LVEF (P < .001) and PFR (P < .02) were significantly 
lower in obese subjects with central fat distribution than in 
lean controls. In contrast, LVM and LVM/H did not differ 
between the two groups (Table 2). 
Correlations 
WHR correlated directly with fibrinogen (r = .47, 
P < .05) and inversely with tPA2 (r =- .48 ,  P < .05); 
duration of obesity correlated directly with factor VII 
activity (r = .49, P < .05) and tPA1 (r = .48, P < .05). In 
addition, LVEF correlated inversely with tPA1 (r = -.55, 
P < .001), PAI (r =- .69 ,  P < .001), and fibrinogen 
(r = -.51, P < .002) (Fig 1). PFR correlated inversely with 
factor VII activity (r = -.50, P < .05). 
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Table 2. Measurements of Hemostatic Function and Left Ventricular 
Structure and Function in Lean and Obese Subjects 
Measure Lean (n = 20) Obese (n = 19) 
Factor VII activity (%) 79 +- 11 105 ~- 18" 
Fibrinogen (g/L) 3.4 _+ 0.7 4.5 -+ 0.8* 
Plasminogen (mg/dL) 9.7 -+ 0.8 13.2 _+ 2* 
PAl (U/mL) 3.2 -+ 0.3 4.9 +- 2* 
tPA1 (ng/mL) 4.8 -+ 0.7 5.9 -+ 1.61" 
tPA2 (ng/mL) 29 + 4 23 -+ 12:1: 
LVM (g) 135 _+ 35 155 -+ 42 
LVM/H (g/m) 81 -+ 25 95 -+ 20 
LVEF (%) 65.5 - 4 56 -+ 10" 
PFR (EDV/s) 3.55 -+ 0.8 2.9 -+ 0.61" 
Abbreviation: EDV, end diastolic volume. 
*P < .001 v lean. 
1.P < .02 v lean. 
~:P < .05 v lean. 
Multiple regression analyses indicated that WHR and 
PAI were independent predictors of LVEF levels. 
DISCUSSION 
This study indicates that obese subjects with central body 
fat distribution may be characterized by abnormalities in
coagulation function and fibrinolytic activity. These in- 
cluded higher levels of factor VII antigen, fibrinogen, 
plasminogen, PAl activity, and basal tPA, and lower levels 
of post-venous-occlusion tPA.
Some of these abnormalities were correlated with mea- 
surements of left ventricular function such as LVEF and 
PFR. These data are consistent with the indication that the 
risk of cardiovascular disease is higher in centrally obese 
than in lean subjects. 1,23,24 
In fact, elevated fibrinogen and factor VII are reported as 
risk factors for cardiovascular disease. 5,7 Moreover, either 
may be considered an expression ofelevated turnover of the 
coagulation pathway and may be involved in the pathogen- 
esis of ischemic heart disease. 5,25 In the current study, 
increased levels of these coagulation factors have been 
found in subjects with central obesity. Moreover, fibrinogen 
was directly correlated with WHR and factor VII was 
directly correlated with duration of obesity, indicating an 
associatien among long duration of obesity, body fat distri- 
bution of central type, and changes in coagulation function. 
In these subjects, fibr!nogen was also inversely correlated 
with LVEF, and this may support a relationship between 
coagulation activity and silent left ventricular dysfunction. 
These data may be of interest, since general epidemiologi- 
cal studies uggest that high levels of fibrinogen and factor 
VII may be of casual significance in the development of
ischemic heart disease. 26 Unlike factor VII, fibrinogen isan 
acute-phase protein and increases in response to a number 
of stimuli. 27 However, clinical situations in which fibrinogen 
levels are high are also characterized by an increase in 
incidence of venous thrombosis, indicating that this factor 
has an important role in thrombogenesis. 5 Fibrinogen is 
also a major determinant of blood viscosity, which, if 
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Fig 1. Correlation between LVEF and coagulation and fibrinolytic 
measurements in lean ([3) and obese (A) subjects. 
increased, probably has a casual role in coronary heart 
disease. 28 
Our data indicate a hypercoagulable state associated 
with a depressed left ventricular function in subjects with 
central obesity. 
It has been recently reported that elevated PAl levels are 
associated with an increased recurrence of myocardial 
infarction. 29,3° In addition, increased PAI levels may be 
detectable in patients with coronary spastic angina. 31 
The relationships between central obesity and fibrinolytic 
activity have been well investigated by Landin et al. 8 They 
reported that a high WHR in obesity was associated with an 
impaired fibrinolytic activity. In addition, Vague et a132 have 
provided evidence that hyperinsulinemia may be an impor- 
tant reason for the impaired fibrinolytic activity. 
In our study, the role of hyperinsulinemia in promoting 
depressed fibrinolytic activity remains uncertain. In fact, 
despite insulin levels that were higher in obese than in lean 
subjects, no evidence indicated an independent effect of 
fasting insulin on the change in fibrinolytic activity. 
In the present study, increased PAI and a depressed 
fibrinolytic activity have been demonstrated in subjects with 
central obesity. WHR and PAI activity remained the best 
predictors of LVEF in multiple regression analysis. This 
indication is further supported by results of the European 
Concerted Action on Thrombosis and Disabilities (ECAT) 
study. 6In this study, a decreased pump function associated 
with increased PAl and decreased fibrinolytic activity both 
before and after stimulation by venous occlusion has been 
reported. An explanation for the mechanisms responsible 
for the abnormalities in hemostatic function detectable in
our obese subjects remains unclear. They might indicate 
that it is possible to detect early suitable markers of 
atherosclerosis in subjects with central obesity. This is also 
supported by lower HDL levels and higher apo B and 
lipoprotein(a) values in obese than in lean comparable 
subjects. 
In conclusion, obese subjects with central body fat 
distribution showed an atherogenic profile characterized by
metabolic and hemostatic abnormalities associated with 
silent left ventricular dysfunction. Further prospective data 
must be provided to demonstrate if cardiac events occur 
more frequently in obese than in lean subjects. 
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